• 10.12.2019 – 01:45

  UCB Pharma

  UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

  Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...

  more

• 06.12.2019 – 03:00

  Fresenius Kabi Deutschland GmbH

  

  2

  Medical experts highlight nutrition survey data during 20th PENSA Congress 2019 in Hong Kong

  more

• 14.02.2019 – 07:30

  Gerresheimer AG

  Gerresheimer back on growth path and sets course for the future

  Duesseldorf (ots) - - Revenues at constant exchange rates up 4.3% in the financial year 2018 to EUR 1,406.7m - Adjusted EBITDA at constant exchange rates at EUR 307.5m, excluding the Advanced Technologies Division and other one-off effects, and despite substantially negative energy costs and resin prices - Strong adjusted net income after non-controlling ...

  more

  One document

• 01.02.2019 – 11:02

  Brenntag AG

  Brenntag UK and Ireland announces the distribution of 3M Glass Bubbles and Boron Nitride fillers into the polymers and rubber sectors

  Dear all, Please find attached a press release regarding the announcement of Brenntag UK and Ireland on the distribution of 3M Glass Bubbles and Boron Nitride fillers into the polymers and rubber sectors. For further information please see the press release. Please do not hesitate to contact us if you have further ...

  more

• 11.10.2018 – 07:46

  Gerresheimer AG

  Andreas Schütte steps down from Management Board of Gerresheimer AG

  Düsseldorf (ots) - Andreas Schütte (56) will step down from the Management Board of Gerresheimer AG at his own request as of February 28, 2019 in order to pursue new career challenges. The Supervisory Board of Gerresheimer AG approved this wish at its meeting yesterday. Andreas Schütte has served on ...

  more

  One document